MEDIFAST INC
$ 10.43
-2.07%
26 Feb - close price
- Market Cap 114,639,000 USD
- Current Price $ 10.43
- High / Low $ 10.77 / 10.34
- Stock P/E N/A
- Book Value 19.29
- EPS -1.66
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.09 %
- 52 Week High 15.46
- 52 Week Low 10.10
About
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Analyst Target Price
$12.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-03 | 2025-08-04 | 2025-04-28 | 2025-02-18 | 2024-11-04 | 2024-08-05 | 2024-04-29 | 2024-02-20 | 2023-11-06 | 2023-08-07 | 2023-05-01 |
| Reported EPS | -1.65 | -0.21 | 0.22 | -0.07 | 0.1 | 0.35 | 0.92 | 0.66 | 0.55 | 2.12 | 2.77 | 3.67 |
| Estimated EPS | -0.45 | -0.3 | -0.22 | 0.78 | 0.2424 | -0.28 | 0.39 | 0.78 | 0.96 | 1.07 | 1.44 | 2.4 |
| Surprise | -1.2 | 0.09 | 0.44 | -0.85 | -0.1424 | 0.63 | 0.53 | -0.12 | -0.41 | 1.05 | 1.33 | 1.27 |
| Surprise Percentage | -266.6667% | 30% | 200% | -108.9744% | -58.7459% | 225% | 135.8974% | -15.3846% | -42.7083% | 98.1308% | 92.3611% | 52.9167% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Previous Dividend Records
| Nov 2023 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2023-11-07 | None | None | None | None | None | None | None | None | None |
| Amount | $1.65 | $1.65 | $1.65 | $1.64 | $1.64 | $1.64 | $1.64 | $1.42 | $1.42 | $1.42 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MED
2026-02-25 03:52:31
The average one-year price target for Medifast (MED) has been reduced by 20% to $12.24 per share, down from $15.30. This new target represents a 16.68% increase from its last reported closing price of $10.49. Institutional ownership in Medifast has seen a decrease in the number of funds reporting positions, although the average portfolio weight dedicated to MED has slightly increased.
2026-02-24 13:51:31
Medifast's Q4 2025 results surpassed revenue expectations due to an early positive impact from its metabolic health-focused business model and improved coach productivity. Despite beating revenue estimates, the company reported a significant GAAP EPS miss and provided Q1 2026 guidance below analyst expectations. The article highlights key analyst questions regarding coach productivity, revenue stabilization, new product offerings for GLP-1 users, and the impact of cost reductions.
2026-02-24 08:51:31
Medifast reported Q4 results that exceeded revenue forecasts, attributing it to a shift towards a metabolic health model and improved coach productivity. Although revenue is still declining year-over-year, CEO Dan Chard noted promising indicators, like a 6% increase in coach productivity. Analysts focused on the durability of these gains, revenue stabilization, new products for GLP-1 users, and the impact of cost-cutting measures, with Medifast anticipating $30 million in annual savings.
2026-02-23 22:53:30
Medifast exceeded Q4 revenue forecasts, driven by a new metabolic health strategy and improved coach productivity, despite a decline in GAAP EPS and EBITDA. Analysts focused on the sustainability of coach gains, revenue stabilization, GLP-1 product support, and the impact of cost-cutting measures. The company is looking to new product rollouts and continued restructuring for future growth.
2026-02-21 22:52:31
Wall Street Zen downgraded Medifast (NYSE:MED) from "hold" to "sell," aligning with Weiss Ratings' "sell" stance, leading to a consensus "Reduce" rating and a $12.00 target price. Despite beating quarterly revenue and EPS estimates, the company issued weak guidance for FY 2026 and Q1 2026, showing negative margins and return on equity. Institutional investors hold approximately 95.5% of the shares, with several funds recently increasing their positions.
2026-02-20 13:48:36
Medifast announced that its OPTAVIA metabolic health system is now eligible for reimbursement through Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA), allowing clients to save up to 40% on program costs. This move is significant as over 90% of U.S. adults are metabolically unhealthy, and OPTAVIA's science-backed approach, including Metabolic Synchronization™, aims to reverse metabolic dysfunction by reducing visceral fat and preserving lean muscle mass. Medifast plans to launch new products in 2026 to further support metabolic health, reinforcing its commitment to scientific solutions and comprehensive behavioral support.
